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The risk of prostate cancer is known to be elevated in carriers of germline mutations in BRCA2, and possibly also in carriers of BRCA1
and CHEK2 mutations. These genes are components of the ATM-dependent DNA damage signalling pathways. To evaluate the
hypothesis that variants in ATM itself might be associated with prostate cancer risk, we genotyped five ATM variants in DNA from 637
prostate cancer patients and 445 controls with no family history of cancer. No significant differences in the frequency of the variant
alleles at 5557G4A (D1853N), 5558A4T (D1853V), ivs38-8t4c and ivs38-15g4c were found between the cases and controls.
The 3161G (P1054R) variant allele was, however, significantly associated with an increased risk of developing prostate cancer (any G
vs CC OR 2.13, 95% CI 1.17–3.87, P¼0.016). A lymphoblastoid cell line carrying both the 3161G and the 2572C (858L) variant in
the homozygote state shows a cell cycle progression profile after exposure to ionising radiation that is significantly different to that
seen in cell lines carrying a wild-type ATM gene. These results provide evidence that the presence of common variants in the ATM
gene, may confer an altered cellular phenotype, and that the ATM 3161C4G variant might be associated with prostate cancer risk.
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Prostate cancer is the second most common malignancy and the
second commonest cause of cancer deaths in men in the European
Union, with 143000 new cases and 60000 deathsyear
 1 (GLOB-
CAN 2000, www-dep.iarc.fr). The aetiology of prostate cancer is
poorly understood. Prostate cancer is known to aggregate in
families, indicating that genetic susceptibility may be important,
but the genes involved are largely unknown. Linkage studies in
multiple case families have suggested susceptibility loci on
chromosomes 1q24, 1q42, 1p36, 8p22–23, 17p, 20q13 and Xq
(see recent reviews by DeMarzo et al, 2003; Gronberg, 2003) but
none have been definitively replicated. As a consequence of these
linkage studies, variants in prostate cancer families have been
identified in several genes including Macrophage Scavenger
Receptor 1(MSR1), 20-50-oligoadenylate-dependent ribonuclease L
(RNASEL) and ELAC2 (chromosome 17p11/HPC2 region) (re-
viewed in Simard et al, 2003), but again none have been reliably
associated with risk.
Several independent studies have demonstrated that individuals
with germline mutations in BRCA2 are at increased risk of prostate
cancer (The Breast Cancer Linkage Consortium, 1999; Edwards
et al, 2003; Giusti et al, 2003). There is also some evidence for an
increased risk in carriers of BRCA1 mutations (Thompson et al,
2002). More recently, Seppala et al (2003) have found that the
CHEK2 variant 1100delC, known to be associated with an
increased risk of breast cancer, is also associated with an increased
risk of prostate cancer, and Dong et al (2003) found that this and
other missense variants in CHEK2 occurred at increased frequency
in prostate cancer cases. The proteins encoded by the BRCA1 and
BRCA2 genes participate in the maintenance of genomic stability
through their involvement in the homologous recombination
pathway for the repair of DNA double-strand breaks and
transcription coupled repair and the CHEK2 protein is also
involved in DNA damage signalling pathways. BRCA1 and CHEK2
are both phosphorylated in response to DNA damage in an ATM-
dependent fashion (Matsuoka et al, 2000). Thus, we hypothesised
that the ATM gene, whose protein functions upstream of these
known susceptibility genes, could also be a mutation target in
prostate cancer.
In a preliminary study by Hall et al (1998), germline mutations
in ATM were identified in three out of 17 (17.6%) prostate cancer
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spatients who showed a severe late response to radiation therapy
and in whom most or all of the ATM gene was examined, while no
such mutations were found in the control group. In this same
study, the 5557G4A ATM sequence variant was found in 35% of
cases compared with the reported population frequency of 15%.
This variant has been found to modulate the penetrance of
hereditary nonpolyposis colorectal cancer in carriers of germline
MLH1 and MLH2 mutations (Maillet et al, 2000). Loss of
heterozygosity of chromosome 11q, the location of the ATM gene,
has also been reported in metastatic prostate carcinoma (Ruijter
et al, 1999).
In order to assess whether ATM variants play a pathogenic role
in prostate cancer development, we compared the frequencies of
five ATM single-nucleotide polymorphisms (SNPs) 5557G4A,
5558A4T, 3161C4G, ivs38-8t4c, ivs38-15g4c in 618 British
prostate cancer cases and 445 controls. In addition, the cellular
phenotype of a lymphoblastoid cell line carrying the 3161G variant
allele in a homozygote state was evaluated.
MATERIALS AND METHODS
Subjects
Subjects were obtained from a study of prostate cancer cases
treated at the Royal Marsden NHS Trust over the period 1993–
2002, as previously described (Eeles et al, 1999). The patients were
unselected for age or family history. The current study included
637 Caucasian cases diagnosed between ages 43 and 86 years.
Controls
Controls were recruited from two series. Series one comprised of
spouses of patients enrolled in a population-based study of
colorectal cancer in the UK (84 males, 86 females) Series 2
(n¼275) were male controls from a different population-based
case–control study of early-onset prostate cancer. These controls
were chosen from the same general practitioners as controls in the
case–control study, and were therefore recruited from across the
UK. Controls had no personal history of cancer. Individuals whose
ethnic group was recorded as non-white were excluded from both
the case and control series.
Lymphoblastoid cell lines
A lymphoblastoid cell line (LCL) (HA220) was established by
infection with Epstein–Barr virus from a breast cancer patient
carrying the ATM 3161G variant in the homozygous state. This
individual carried none of the other SNPs investigated in this
present study; however, the 2572T4C variant, which is in strong
linkage disequilibrium with 3161C4G, was also present. LCLs
from a subject with a wild-type ATM gene (IARC 1104) and a
classical AT patient carrying truncating mutations on both alleles
(IARC AT11 Q2002X; Q2714X) were used for comparative
purposes in this study. These two lines were obtained from Dr G
Lenoir. The cells were routinely maintained at 371Ci n5 %C O 2 in
RPMI 1640 Glutamax-1 medium (Gibco, Invitrogen Corporation,
Cergy-Pontoise, France) containing 10% heat-inactivated foetal
calf serum (Integro b.v.i, Zaandan, Holland) and 1% penicillin/
streptomycin (Biochrom AG, Berlin, Germany).
Cell cycle distribution by flow cytometry
Two flasks were set-up containing 20ml of stock cultures
(5 10
5cellsml
 1). One flask served as an unirradiated control
and the second was treated with 5Gy of ionising radiation from a
Cs
137 source. A volume of 4ml was harvested immediately from
each flask (time 0h) and then 24 and 48h postirradiation. The cells
were centrifuged at 1100r.p.m. for 5min at 41C, washed once in
PBS and frozen at  801C in citrate/sucrose/DMSO buffer
(CycleTEST
TM PLUS staining kit Becton Dickinson, Franklin
Lakes, NJ, USA) until being evaluated. Just before analysis, the
cells were resuspended in a trypsin solution for 10min at room
temperature, followed by the addition of RNAse buffer (10min at
room temperature) and stained with a solution of propidium
iodide. The samples were subsequently analysed with a FACS
Calibur flow cytometer (Becton Dickinson). The ModFit LT cell
cycle analysis software was used to estimate percentage of cells in
the G0–G1, S and G2–M phases. At least three independent
experiments were done for each cell line and the G2/G1 ratios were
calculated.
DNA extraction
DNA was extracted from blood samples by routine methods with
the inclusion of a second proteinase K digestion at 501C (Edwards
et al, 1997). DNA was dissolved in 0.2–0.4ml of water (BDH,
Poole, UK) and stored at  201C until required.
ATM SNP analysis
The frequency of the ATM SNPs was assessed using either high-
performance liquid chromatography (DHPLC) or restriction
fragment length polymorphism (RFLP) after polymerase chain
reaction (PCR) amplification of the appropriate ATM fragment.
For DHPLC analysis, PCRs of 40ml were performed in 96-well
plates to amplify two regions using the primers listed in Table 1.
Each PCR contained 25ng DNA, 200mM each dNTP, 3mM MgCl2,
0.4mM primer and 1.5U Platinum Taq polymerase (InVitrogen
SARL, Cergy Pontoise, France). The cycling conditions were 941C
5min, followed by 35 cycles of 941C3 0s ,5 2 1C (exon 24) or 571C
(exon 39) 30s, 721C 30s, with a final extension at 721C for 5min.
The PCR products were denatured for 5min at 951C and then
slowly cooled to permit reannealing and formation of homo-
duplexes and heteroduplexes.
DHPLC analysis of exon 24 (containing the 3161C4G variant)
and exon 39 (containing the 5557G4A, 5558A4T, ivs38-8t4c and
ivs38-15g4c variants) was performed on a WAVE DNA Fragment
Analysis System (Transgenomic, Omaha, NE, USA). Buffer
gradient and temperature conditions were calculated using the
WAVEmaker software (version 3.4.4. Transgenomic). In order to
establish whether the homoduplexes contained a wild-type or
variant sequence, a second DHPLC analysis was carried out mixing
these samples with a DNA sample containing a wild-type sequence.
For all samples displaying aberrant DHPLC chromatograms, the
PCR was repeated and the sequences of these PCR products
determined using an ABI 3100 Genetic Analyser. The primers used
for sequencing were the forward and reverse PCR primers in
Table 1.
The frequency of the 3161C4G SNP was assessed in the DNAs
of all the controls and 226 of the cases using restriction
endonuclease digestion making use of the fact that this SNP
occurs at a naturally occurring AlwI site (Table 1). The PCRs were
carried out in a total volume of 25ml containing 25ng DNA, 100mM
each dNTP, 2mM MgCl2, 0.4mM primer and 1.5U Platinum Taq
polymerase (InVitrogen SARL, Cergy Pontoise, France). The
cycling conditions were 941C 5min, followed by 40 cycles of
941C3 0 s ,5 9 1C3 0 s ,7 2 1C 30s, with a final extension at 721C for
5min. The PCR product was digested with AlwI according to the
manufacturer’s instructions and the fragments analysed by
electrophoresis on a 3% NuSieve agarose gel. DNA samples known
to be carrying the mutant allele were included in each analysis,
with the genotype of the samples being determined by the banding
pattern observed on the gels (the 494bp PCR product being cut
into 305 and 189bp fragments if the wild-type allele is present). A
random sample of DNAs was also analysed by direct sequencing of
ATM variants and prostate cancer risk
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sthe corresponding exon and complete concordance between the
different techniques was observed (data not presented).
Statistical methods
Analyses of genotype frequencies for each polymorphism were
based on all cases and controls successfully typed for each
polymorphism. Departures from Hardy–Weinberg equilibrium
were assessed by comparing the observed and expected genotype
frequencies. Differences in genotype frequencies between cases
and controls were tested using standard w
2-tests. Odds ratios (OR)
and confidence limits (CI) were calculated by standard methods.
For the 5557G4A polymorphism where there was more than two
genotypes, 95% floating confidence limits (FCIs) were also
computed as suggested by Easton et al (1991). An ANOVA
analysis was used to compare the G2/G1 ratios between the control,
AT and HA220 cell lines and a t-test to compare the results
obtained for HA220 and the group of six control cell lines. All
computations were calculated using STATA version 7.0 (Stata
Corporation).
RESULTS
The genotype frequencies for the five SNPs in cases and controls,
with corresponding ORs, are shown in Table 2. The maximum
number of cases and controls for whom a genotype was available
was 628 and 445, respectively. The frequencies of the variant alleles
5557A, 5558T and 3161G are in good agreement with previous
studies in the Caucasian population (Dork et al, 2001; Spurdle et al,
2002; Mauget-Faysse et al, 2003). The frequency of the intronic
SNPs ivs38-15g4c (Thorstenson et al, 2001) and ivs38-8t4c
(Sandoval et al, 1999) have previously only been determined in a
small number of individuals. The ivs38-15 is the rarer of the two
variants, the c allele being present at an allele frequency of 0.004,
while the ivs38-8c allele is found at a frequency of 0.036. In
agreement with previous observations, the ivs38-8t4c variant was
in strong linkage disequilibrium with the G5557A variant. The
allele frequency did not differ significantly between the two series
of controls, or between male and female controls, for any of the
SNPs examined. We therefore combined our control series for the
main analysis.
We found no significant differences in the genotype distribution
between cases and controls for the SNPs 5557, 5558, ivs38-8 and
ivs38-15. The 3161G allele was, however, associated with an
increased risk of developing prostate cancer (any G vs CC OR 2.13,
95% CI 1.17–3.87; P¼0.016) (Table 2).
A lymphoblastoid cell line carrying both the 3161G variant in
the homozygote state and the 2572T4C variant in exon 19
(F858L), which are in strong linkage disequilibrium, was available.
The line originated from a German breast cancer patient who was
diagnosed at age 38 and suffered from a local relapse by age
40. Her father died from prostate cancer, but she had no family
history of breast cancer. ATM protein was found to be expressed at
Table 1 Primers and restriction enzymes for ATM exon and SNP analysis
ATM exon or SNP Technique Primers Restriction enzyme and digestion conditions
Exon 39 DHPLC Forward: 50-GGCAGATTAATCTATCATCTTTTAGA-30
Reverse: 50-ATTCTGTTTCATTATGGTAATGGC-3’
Fragment size 372bp
Exon 24 DHPLC Forward: 50-TTCATATTCAACCACAGTTC-30
Reverse : 50-TGTAAGACATTCTACTGCCATC-30
Fragment size 224bp
3161C4G (P1054R) RFLP Forward: 50-AGCACAGAAAGACATATTGGAAG-30 o/n at 371C1 0UAlwI
Reverse: 50-ACTATGTAAGACATTCTACTGCC-30
Fragment size 494bp
Table 2 Association between ATM SNPs and prostate cancer
Rare allele frequency
SNP Controls Cases Cases (%) Controls (%) OR 95% CI or FCI P-value
5557G4A 0.166 0.151 GG 457 (72.7) 309 (69.4) 1 0.87–1.16
GA 153 (24.4) 124 (27.9) 0.83 0.66–1.06
AA 18 (2.9) 12 (2.7) 1.01 0.49–2.11 0.43
5558A4T 0.005 0.004 AA 623 (99.2) 440 (99) 1
AT 5 (0.8) 4 (1) 0.88 0.24–3.31 0.85
ivs38-8t4c 0.036 0.036 TT 585 (93.2) 414 (93.0) 1
TC 41 (6.5) 30 (6.7)
CC 2 (0.3) 1 (0.3)
C carriers 43 (6.8) 31 (7.0) 0.98 0.60–1.58 0.96
ivs38-15g4c 0.004 0.008 GG 618 (98.4) 441 (99.1) 1
GC 10 (1.6) 4 (0.9) 1.78 0.55–5.72 0.32
3161C4G 0.018 0.038 CC 578 (92.6) 402 (96.4) 1
CG 45 (7.2) 15 (3.6)
GG 1 (0.2) 0 (0)
G carriers 46 (7.4) 15 (3.6) 2.13 1.17–3.87 0.016
ATM variants and prostate cancer risk
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swild-type levels in the line HA220 as revealed by immunoblotting
(data not shown). The cell cycle profile after exposure to 5Gy
was determined in this lymphoblastoid line (HA220) in com-
parison with a LCL carrying a wild-type or a mutant ATM gene.
At zero time (T0h Figure 1) there was no differences in the
proportion of cells in the different phases of the cell cycle and
thus in the G2/G1 ratios between HA220, the control and AT cell
lines. After exposure to 5Gy of ionising radiation the G2/G1
ratio, representative of the percentage of cells which accumulate in
G2, is significantly higher in the AT line, IARC AT11, than the
control line, IARC 1104 at both 24h (P¼0.001) and 48h
(P¼0.000014). The ANOVA analysis of the observed cellular
response, adjusted for time, for HA220 shows that it is
intermediate between that seen in these two cell types. The G2/
G1 ratio was significantly higher than that seen in the control cell
line after exposure (G2/G1 HA220 vs IARC 1104 P¼0.033) yet
lower than that seen in the AT line (G2/G1HA220 vs IARC AT11
P¼0.000005). When this profile is compared with the results
obtained from the analysis of six cell lines carrying a wild-type
ATM gene assayed under similar conditions (Ange `le et al, 2003)
the response in HA220 it is not statistically different 24h after
exposure to ionising radiation. However, at 48h postirradiation
there was significantly more cells in the G2 phase of the cell cycle
than in the treated control cell lines (HA220 vs control cell lines
48.6273.47 vs 41.2274.63% P¼0.0296 (t-test) full data set not
shown).
DISCUSSION
We have investigated the possible association between five ATM
sequence variants and an increased risk of prostate cancer. Of the
SNPs investigated, we found evidence for an association with
prostate cancer only for the 3161C4G (1054P4R) variant. This
association, while significant at the 0.016 level, is not definitive and
will require further evaluation in other case–control studies.
Conversely, modest associations with some of the other SNPs
cannot be definitively excluded. This is particularly true of the
5558A4T and ivs38-15g4c variants, which are rare and for which
the upper 95% CI on the OR exceeds 3.
Assuming that the association between 3161G variant allele and
prostate cancer is not due to chance, there are essentially three
possible explanations for the association: a difference in frequency
between the populations from which the cases and controls were
drawn (population stratification), linkage disequilibrium or a true
causal association. Although population stratification remains a
possibility, the similarity in frequency between the two control
groups, and the fact that one of the control groups were chosen
from the general practitioners of prostate cancer cases makes this
less likely. To distinguish between a causal association and linkage
disequilibrium, it would be necessary to evaluate all variants
occurring on the same haplotype as 3161G. Strong linkage
disequilibrium has been found between 3161G (P1054R) and the
variant allele at 2572C (F858L). It has also been found to occur in
cis to the splicing mutation 3576G to A found in some AT patients
of South or South East European descent (Sandoval et al, 1999)
although this splicing mutation was neither present in the patient
HA220 nor in any other breast cancer patient carrying the 3161G
allele (Dork et al, 2001). There may, however, be other variants on
this haplotype (including noncoding alterations) that have not
been studied.
The 3161G4C variant is located in the b-adaptin domain
of the ATM protein and has been suggested to be linked to an
increased cancer risk (Vorechovsky et al, 1996, 1999). It has been
reported as a pathogenic mutation in a B-cell chronic lymphocytic
leukaemia patient (Stankovic et al, 1999). Larson et al (1997/8)
found that the variant genotype was present in 13.6% of breast
cancers with an affected sister, compared with 3.5% of breast
cancers without a family history and 3.2% of the controls. The
results from subsequent breast cancer studies do not provide
strong support for this association (Dork et al, 2001; Sommer et al,
2002; Spurdle et al, 2002). A combined analysis of these three
studies, however, provides some suggestion of an association
between 3161G and breast cancer risk (OR after stratification by
study 1.34, 95% CI 0.99–1.83). Dork et al (2001) found a higher
proportion of node-positive tumours was observed in P1054R
heterozygous breast cancer patients (Po0.01) suggesting that this
ATM variant could modulate the course or prognosis of breast
carcinoma. Interestingly, the LCL established from a homozygous
carrier of the 3161G allele shows a cell cycle progression profile
with time after exposure to ionising radiation that is intermediate
between that seen for LCLs carrying a wild-type or a mutant ATM
gene. In addition, this line and five other LCLs established from
breast cancer patients carrying the linked 2572T4C and 3161
C4G variants in the heterozygous state had higher levels of
micronuclei induction after exposure to ionising radiation
compared with LCLs with a wild-type ATM gene (Gutie ´rrez-
Enrı ´quez et al, 2004) suggesting that the presence of this variant
may influence the cellular response after exposure to ionising
radiation.
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Figure 1 Cell cycle analysis at 0, 24 and 48h after exposure to 5Gy
ionising radiation in LCLs carrying either a wild-type ATM (IARC 1104) or a
mutated ATM (AT11) or the linked 3161G and 2572C ATM variants in the
homozygote state (HA220).
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